MỘT SỐ ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ UNG THƯ VÚ VI XÂM NHẬP TẠI BỆNH VIỆN K

Abstract

Objective: Describe the clinical, paraclinical characteristics and treatment outcomes of patients with microinvasive breast carcinoma (MIC) at K Hospital. Methods: A descriptive retrospective study was conducted on female patients diagnosed with MIC from 2015 to 2022 at K Hospital. Result: 76 patients with available follow-up information were included. The median follow-up time was 48 months (range: 9-94 months). The 5-year disease-free survival (DFS) and 5-year overall survival (OS) rates are 90% and 100%, respectively. The mean age of the study group was 49.61 ± 10.4 years. The average tumor size was 3.2 ± 1.6 cm, with 40 patients (52.6%) having tumors ≥ 3 cm. The majority of patients (94.7%) presented with palpable mass, and the incidence of nipple discharge was 13.1%. Microcalcifications were observed in 37 patients (48.7%) on mammography. Associated carcinoma in situ lesions included 72 DCIS (94.7%), 1 LCIS (1.3%) and 3 Paget's disease (3.9%). Most DCIS lesions have high histologic grade, accounting for 84.2%. The rate of lymph node metastasis was 3.9%, and estrogen receptor positivity was observed in 32 patients (42.1%). Her2 of microivasive components results were available for 61 patients, with 51.3% show positive Her2 status. The proportions of patients receiving adjuvant radiation, chemotherapy, targeted therapy, and endocrine therapy were 22.4%, 82.9%, 23.7%, and 42.1%, respectively. 4 cases were recurrence, including 2 local and regional recurrences and 2 distant metastases. Conclusion: MIC presents various clinical and paraclinical features that differ from DCIS. The treatment of MIC includes surgery, chemotherapy, and endocrine therapy, with the possibility of incorporating targeted therapy for good results. Long-term surveillance is essential for a more comprehensive evaluation of potential recurrence.